The case for & against
Bull & Bear analysis
Alexandria Real Estate Equities, Inc. (ARE) is a leading real estate investment trust (REIT) specializing in high-quality office and laboratory space for companies in the life sciences, technology, and healthcare sectors. Positioned as a dominant player within the health and life sciences real estate market, Alexandria's unique portfolio centers around innovation and state-of-the-art facilities, particularly in urban and technology-driven areas such as San Diego. The company is fundamentally tied to themes of biotechnology growth and advancements in medical research.
Bull says
- ↑95.4% occupancy at 427k RSF San Diego research hub driving rental income.
- ↑2.12% dividend yield supports income investors amid market volatility.
- ↑$3.6B available liquidity funds developments and lease renewals.
- ↑Short interest down 12.1% signals improving institutional sentiment.
- ↑Book-to-price ratio of 2.65 and low volatility suggest value and stability.
- ↑Positive balance-sheet strength indicated by solid QS factor score.
Bear says
- ↓Q2’26 net loss of $(0.43)/share and EPS guide down 13.5%.
- ↓Net debt/Adjusted EBITDA at 7.0x poses significant leverage risk.
- ↓Same-property NOI fell 10.6% due to large lease expirations.
- ↓Consensus 'Reduce' rating with more sell/hold than buy.
- ↓Negative profitability and earnings yield factors signal earnings pressure.
- ↓High interest-rate sensitivity threatens cash flows as rates climb.
Investment themes with ARE
Nuclear energy production and related companies
Stable income from diversified rental housing portfolios
Earnings Call · Q4 2023 · Mgmt. Guidance
Transcript signals
Bull points
- the trajectory of the industry is positive, translating long-term, into a healthy and expanding tenant base.
- we expect healthy levels of internal research and M&A to continue through 2024 and beyond.
- Our ARR from biotechs with marketed products increased to 17% compared to 14% in 3Q.
Bear points
- Over the next decade, the top 20 pharma are staring down approximately $200 billion of lost revenue as patents expire, new competitors enter the market and a subset of medicines become subject to potential price setting by Medicare through the recently enacted IRA legislation.
- We made a strategic decision not to go forward with the contemplated redevelopment of that building to in part to state and local challenging state and local governmental policies.